University College Cork
|As first author||5|
|As last author||150|
R Paul Ross(219)
Paul D. Cotter(139)
Cormac G M Gahan(77)
Paula M. O'Connor(52)
Roy D. Sleator(38)
Mary C. Rea(37)
Pat G. Casey(32)
Gerald F Fitzgerald(27)
Lorraine A Draper(21)
Caitriona M Guinane(20)
Karen M. Daly(12)
Susan A. Joyce(11)
Eamonn P Culligan(11)
... and 126 others
These arethe10 unique sources for Colin Hill's 362 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Maynooth University||2|
|Ireland -> Maynooth University -> PubMed||1|
|Ireland -> Teagasc||154|
|Ireland -> Teagasc -> PubMed||105|
|Ireland -> Trinity College Dublin||1|
|Ireland -> Trinity College Dublin -> PubMed||1|
|Ireland -> University College Cork||228|
|Ireland -> University College Cork -> PubMed||178|
|Ireland -> University of Limerick||1|
|Ireland -> University of Limerick -> PubMed||1|
A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a BSH1 enzyme of SEQUENCE ID NO: 1, or a functional variant thereof; a BSH1 enzyme of SEQUENCE ID NO: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of BSH1.
An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide having potent antibacterial activity against Lactobacillus delbrueckii subspecies bulgaricus, Listeria and Staphylococcus aureus.
An isolated bacteriophage MR299-2 or NH-4 deposited under NCIMB Deposit Accession Nos. 41729 and 41730, respectively, is described. The phages have lytic activity against P. aeruginosa strains, including mucoid and CF clinical isolate strains. Variant hages are also described, wherein said variants retain the phenotypic characteristics of said phage and wherein said phage and variants thereof have lytic activity against P. aeruginosa strains.
A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.
The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity.
The invention relates to a gene derivable from the LIPI-3 pathogenicity island of the gram positive pathogen Listeria monocytogenes and to the Listeria monocytogenes cytotoxin, Listeriolysin S. The present invention further relates to the application of Listeriolysin S as a target for diagnostic screening and as a therapeutic agent such as an anti-cancer agent.
The present invention relates to Angiotensin-I-converting enzyme inhibitors and to methods of producing such inhibitors comprising culturing a Lactobacillus strain in the presence of milk proteins. Strains useful in the production of these inhibitors are disclosed. The invention also relates to functional foods comprising such inhibitors.
The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus , strain DPC6026, a sample of which has been deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland on 18th November 2005 under the accession number NCIMB 41354, or a derivative or mutant thereof capable of producing from milk or a milk product, peptides having antimicrobial activity.
The invention provides a probiotic composition to alleviate Salmonella infection in farm animals. The composition may comprise at least one of Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus salivarius sub-species salivarius, and Pediococcus pentosaceus. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.
The production of a spray-dried bacteriocin lacticin 3147 powder is described. The powder is shown to have effective anti-microbial activity in a range of foodstuffs, namely infant milk formulations, powdered soup, yoghurt and cottage cheese. Increased anti-microbial activity was demonstrated when the lacticin 3147 powder was used in conjunction with increased hydrostatic pressure. The process comprises: inoculating a medium with a lacticin 3147-producing strain of bacteria, fermenting the inoculated medium, adjusting the pH of the fermentation to 6.3-6.7, inactivating the bacterial fermentate and evaporating the fermentate.
An antimicrobial which is effective against a range of Gram positive organisms is described. The antimicrobial is the bacteriocin lacticin 3147, which is shown to be effective both in vivo and in vitro against a range of Gram positive organisms.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.